Why Health Care's Seasonal Tailwind Looks Especially Compelling This YearZacks Investment Research • 06/05/26
Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda PromiseSeeking Alpha • 06/05/26
Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 06/05/26
Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/04/26
Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification TranscriptSeeking Alpha • 06/02/26
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness Wire • 06/02/26
Merck exec says company is discussing use of COVID antiviral drug in Ebola responseReuters • 06/01/26
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual MeetingAccesswire • 06/01/26
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?Zacks Investment Research • 05/29/26
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)Business Wire • 05/29/26
Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first.VentureBeat • 05/27/26
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder CancerZacks Investment Research • 05/25/26
Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?Zacks Investment Research • 05/22/26
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.Barrons • 05/22/26